More News! 27 May 2024 New report shows that Swiss biotech capital investment surged last year With a record revenue of $8 billion in 2023, Swiss biotech appears robust in 2024. Delve into the findings of the Swiss Biotech Report 2024. May 27, 2024 - 5 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 18 Apr 2024 Biotech under surveillance: The global impact of the WuXi AppTec controversy Delve into the ongoing controversy involving the Chinese company WuXi AppTec and the possible impact on U.S. national security measures. April 18, 2024 - 9 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 1 Feb 2024 Can gene therapy be the key to restoring hearing loss? Explore gene therapy’s success in treating genetic hearing loss as a child regains hearing at the Children’s Hospital of Philadelphia. February 1, 2024 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 18 Jan 2024 2024 J.P. Morgan Healthcare Conference: key takeaways from the largest biotech gathering of the year Here are some of the key takeaways from the JPM Healthcare Conference that lay the groundwork for what we can expect in 2024. January 18, 2024 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 12 Jan 2024 AI and a brain organoid: can this combo take on supercomputers? Explore the groundbreaking fusion of brain organoids and AI in the creation of Brainoware, the world’s first biohybrid computer. January 12, 2024 - 5 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 8 Jan 2024 Is the biotech industry poised for recovery in 2024? The past few years have been challenging for the industry but 2024 might be the year marking the biotech recovery. January 8, 2024 - 5 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 21 Dec 2023 The big pharma race against deadly RSV steps up in 2023 GSK and Pfizer received FDA approval for their RSV vaccines in 2023. Now, AstraZeneca has joined the race with its latest acquisition. December 21, 2023 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 7 Dec 2023 BIO-Europe 2023: top ten highlights The biopharma community met at Munich in Germany for BIO-Europe 2023, where attendees from across the world took part in networking events to foster collaboration, last month. With a turnout of nearly 6000 participants and more than 150 exhibitors, the event hosted a number of panel discussions. In collaboration with our parent company, life science […] December 7, 2023 - 24 minutesmins - By Dylan Kissane Share WhatsApp Twitter Linkedin Email
News and Trends 6 Dec 2023 A gene editing milestone: The FDA approves CASGEVY, the first CRISPR-based therapy Still a relatively new technology, CRISPR has been heralded in recent years as having the potential to tackle a range of diseases. And now, it has finally proved its worth. In a world first, the U.S. Food and Drug Administration (FDA) has approved CASGEVY – the CRISPR-based gene therapy developed by Vertex Pharmaceuticals and CRISPR […] December 6, 2023 - 6 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 1 Dec 2023 Arvinas raises $350 million; Exonate’s trial reaps success; new cancer drugs discovered Here is Labiotech’s weekly roundup of the latest biotech news. Stay in the loop by subscribing to our newsletter for direct updates to your inbox. The latest biotech news in fundraising In the news this week, biotech Arvinas raises $350 million PIPE American protein degradation company Arvinas has bagged $350 million in a private placement (PIPE). The […] December 1, 2023 - 11 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 20 Nov 2023 M&As: what’s up with the ADC buying spree? Antibody drug conjugates (ADCs) have been much sought-after through investments of late, with big pharma eyeing these drugs developed by various biotechs, to eventually nab them. With yet another ADC being bought by Bristol Myers Squibb, and AbbVie’s proposed $10 billion deal to seize ImmunoGen’s oncology pipeline, are these drugs the golden ticket to targeted […] November 20, 2023 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 17 Nov 2023 With $700 million Q3 rise, U.K. biotech spearheads European recovery The U.K.’s biotechnology landscape has witnessed an impressive surge in funding, clocking a robust £563 million ($700 million) in venture capital and public financings in the third quarter of 2023, according to Biotech Finance. This achievement marks a staggering 48% increase from the previous quarter and sets a formidable pace that is already on track […] November 17, 2023 - 4 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email